Oncomine Dx Target Test – an IVD NGS solution for every lab
contributed by Thermo Fisher Scientific |
With the ongoing development of precision oncology and more and more biomarkers entering routine clinical testing, a true end-to-end IVD solution, consolidating everything into one streamlined workflow, is needed in more pathology laboratories. The Oncomine Dx Target Test, based on next-generation sequencing (NGS), is now available in Europe and offers just that – 46 gene targets, including biomarkers associated with approved and investigative targeted therapies, all from one test, in one workflow, and in four days. Among the biomarkers tested are not only EGFR,ALK,ROS1 and BRAF but also cMET, NTRK1/2/3, RET, ERBB2, and others, currently in clinical trials.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine